EWPI (Emerging World Pharma) Debt-to-EBITDA : 0.00 (As of . 20)


What is Emerging World Pharma Debt-to-EBITDA?

Emerging World Pharma EWPI -99.00% Debt-to-EBITDA is 0.00 as of . 20.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Emerging World Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Emerging World Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Emerging World Pharma's annualized EBITDA for the quarter that ended in . 20 was $0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Emerging World Pharma's Debt-to-EBITDA or its related term are showing as below:

EWPI's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.66
* Ranked among companies with meaningful Debt-to-EBITDA only.

Emerging World Pharma  (OTCPK:EWPI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Emerging World Pharma Debt-to-EBITDA Related Terms

Emerging World Pharma Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Emerging World Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emerging World Pharma Debt-to-EBITDA Chart

Emerging World Pharma Annual Data
Trend
Debt-to-EBITDA

Emerging World Pharma Quarterly Data
Debt-to-EBITDA

EWPI vs ENZB, AOXG: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emerging World Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emerging World Pharma Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emerging World Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Emerging World Pharma's Debt-to-EBITDA falls into.


Emerging World Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Emerging World Pharma's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / N/A
=N/A

Emerging World Pharma's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (. 20) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
Emerging World Pharma (EWPI) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Emerging World Pharma.
Is Emerging World Pharma's Debt-to-EBITDA too high?
Emerging World Pharma's current Debt-to-EBITDA is 0.00.
How does Emerging World Pharma's Debt-to-EBITDA compare to ENZB and AOXG?
Emerging World Pharma's Debt-to-EBITDA of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.66, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Emerging World Pharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emerging World Pharma's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emerging World Pharma stock overvalued right now?
Emerging World Pharma (EWPI) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Emerging World Pharma (EWPI), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emerging World Pharma Business Description

Address Block 11A, Pastoral Road, Sunyani, GHA, 20109
Emerging World Pharma Inc is an investor in generic based pharmaceutical companies manufacturing within developing nations.